
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Role of Endoscopy in Pregnancy: A Review  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Role of Endoscopy in Pregnancy: A Review  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Razjouyan &amp; Maranki, <em>Gastrointestinal Endoscopy</em> 2025  </li>
<li style="margin-left: 0px;">Topic: Endoscopic diagnosis and therapy during gestation  </li>
</ul>
<details><summary><strong>1. Indications for Endoscopy in Pregnant Patients  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Persistent/refractory GI bleeding → urgent upper endoscopy  </li>
<li style="margin-left: 0px;">Severe nausea‑vomiting/abdominal pain w/ ulcer suspicion → consider EGD  </li>
<li style="margin-left: 0px;">Dysphagia or odynophagia → evaluate for infection/erosive esophagitis  </li>
<li style="margin-left: 0px;">Suspected colonic mass or refractory diarrhea → colonoscopy indicated  </li>
</ul>
<details><summary><strong>1.1 Upper Endoscopy Specifics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Mallory‑Weiss tear = most common non‑variceal bleed source  </li>
<li style="margin-left: 0px;">Portal hypertension ⇒ risk of variceal rupture, need urgent EGD  </li>
</ul>
</div></details>
<details><summary><strong>1.2 Lower Endoscopy Specifics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">High suspicion of neoplasm or unexplained diarrhea → colonoscopy  </li>
<li style="margin-left: 0px;">Flexible sigmoidoscopy preferred for IBD assessment (no full prep)  </li>
</ul>
</div></details>
<details><summary><strong>1.3 ERCP / Biliary Indications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Symptomatic choledocholithiasis, biliary pancreatitis, cholangitis → ERCP with stent if needed  </li>
<li style="margin-left: 0px;">Bile‑duct or pancreatic‑duct injury ⇒ therapeutic ERCP  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Peri‑Procedural Considerations &amp; Maternal–Fetal Safety  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Mandatory obstetric consult before any endoscopic intervention  </li>
<li style="margin-left: 0px;">Fetal heart rate monitoring: Doppler pre/post sedation; electronic monitoring after 24 wks gestation  </li>
<li style="margin-left: 0px;">Contraindications: eclampsia, ruptured membranes, imminent delivery, placental abruption  </li>
</ul>
<details><summary><strong>2.1 Timing &amp; Positioning  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Second trimester optimal: organogenesis complete, uterus smaller → less vascular compression  </li>
<li style="margin-left: 0px;">Left lateral tilt or left pelvic tilt mandatory after 24 wks to avoid IVC/aortic compression  </li>
<li style="margin-left: 0px;">Upright sitting reduces vascular pressure; supine avoided in late gestation  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Sedation &amp; Medication Safety (Table 2 summary)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Category B: Meperidine, Propofol (requires anesthesia), Glucagon, Topical lidocaine – generally safe  </li>
<li style="margin-left: 0px;">Category C: Fentanyl (low dose ok), Morphine, Naloxone, Simethicone – use cautiously  </li>
<li style="margin-left: 0px;">Category D: Benzodiazepines – avoid first trimester; midazolam only if essential  </li>
</ul>
</div></details>
<details><summary><strong>2.3 Bowel Preparation &amp; Enemas  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Flexible sigmoidoscopy → tap‑water enema preferred  </li>
<li style="margin-left: 0px;">Polyethylene glycol electrolyte lavage = Category C, low risk  </li>
<li style="margin-left: 0px;">Sodium phosphate solutions = Category C, may cause fluid/electrolyte shifts – use with caution  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Safety Data for Specific Endoscopic Modalities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Upper endoscopy</strong>: 60 pregnant pts (first trimester) → esophagitis 43 %, gastritis 17 %, diaphragmatic hernia 17 %; diagnostic yield for bleed 82 %; no fetal malformations reported.  </li>
</ul>
<details><summary><strong>3.1 Diagnostic Yield &amp; Outcomes  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">83 pregnant vs 48 controls: EGD diagnostic yield 95 % for acute bleed, 50‑82 % for other indications; 62 % esophagitis prevalence; 95 % healthy deliveries, 4 adverse outcomes unrelated to procedure.  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Flexible Sigmoidoscopy in IBD  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">48 pts (suspected/known IBD) → 78 % changed management; no obstetric adverse events reported.  </li>
</ul>
</div></details>
<details><summary><strong>3.3 Colonoscopy Experience  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">20 pts (mostly 2nd trimester): cecum reached 55 %; mild maternal hypotension 2 cases; no fetal distress; unfavorable fetal outcomes comparable to controls.  </li>
</ul>
</div></details>
<details><summary><strong>3.4 Lower GI Endoscopy Across Trimesters  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">100 lower GI procedures: 1st tri 1 AE, 2nd tri 3 AEs, 3rd tri 2 AEs → overall safety across gestation.  </li>
<li style="margin-left: 0px;">Sigmoid volvulus (3rd trimester) – successful endoscopic decompression reported.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Advanced Endoscopic Procedures: ERCP in Pregnancy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Most common advanced procedure due to increased choledocholithiasis risk.  </li>
<li style="margin-left: 0px;">Strong indication required; documented in record; multidisciplinary team essential.  </li>
</ul>
<details><summary><strong>4.1 Timing &amp; Positioning for ERCP  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Preferred second trimester (organogenesis complete, less uterine compression).  </li>
<li style="margin-left: 0px;">Left lateral tilt or pelvic tilt preferred; supine only acceptable in first trimester.  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Radiation Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Fetal threshold 100‑200 mGy (organogenesis weeks 2‑8); deterministic effects &lt;50 mGy not observed.  </li>
<li style="margin-left: 0px;">Typical ERCP exposure .01‑5.77 mGy → well below 10 mGy monitoring limit.  </li>
</ul>
<details><summary><strong>4.2.1 Exposure Data Examples  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Cohort of 15 pts: mean fluoroscopy time 14 s; fetal dose 0.4 mGy (range 0.001‑1.80).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4.3 Techniques to Minimize Radiation (Table 3 summary)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Increase distance from x‑ray tube, bring image receptor close → ↓ dose  </li>
<li style="margin-left: 0px;">Use collimation, brief‑pulse low‑dose mode, avoid digital acquisition  </li>
<li style="margin-left: 0px;">Wire‑guided cannulation, bile aspirate confirmation, cholangioscopy assistance, real‑time transabdominal US guidance  </li>
</ul>
</div></details>
<details><summary><strong>4.4 ERCP Outcomes &amp; Complications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Technical success comparable to non‑pregnant cohorts.  </li>
<li style="margin-left: 0px;">Post‑ERCP pancreatitis ↑ up to 16 % (historical) → recent high‑volume centers report 9.6‑12 %.  </li>
<li style="margin-left: 0px;">Maternal mortality similar to national estimates; preterm labor lower in pregnant cohort (1.87 % vs 11.5 %).  </li>
</ul>
<p><em>End of Part 1 (first 4 major headings). Subsequent sections will cover medication tables, radiation long‑term effects, future directions, and conclusions.</em></p>
</div></details>
</div></details>
<details><summary><strong>5. Medications Used During Endoscopy in Pregnancy  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Sedative and Analgesic Agents  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Meperidine</strong> – FDA Category B; not teratogenic, preferred narcotic for moderate sedation.  </li>
<li style="margin-left: 0px;"><strong>Fentanyl</strong> – Category C; short‑acting, no teratogenicity reported, embryocidal in rats only at high doses; safe in low clinical doses.  </li>
<li style="margin-left: 0px;"><strong>Propofol</strong> – Category B; narrow therapeutic index, requires anesthesia support; first‑trimester safety not well studied.  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Benzodiazepines and Adjuncts  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Midazolam</strong> – Category D; preferred benzodiazepine if unavoidable, avoid in first trimester.  </li>
<li style="margin-left: 0px;"><strong>Diazepam</strong> – Category D; contraindicated in pregnancy.  </li>
<li style="margin-left: 0px;"><strong>Flumazenil</strong> – Category C; limited safety data, used only for reversal of benzodiazepine effects.  </li>
</ul>
</div></details>
<details><summary><strong>5.3 Opioid Antagonists &amp; Others  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Naloxone</strong> – Category B; rescue medication for respiratory depression or hypotension.  </li>
<li style="margin-left: 0px;"><strong>Morphine</strong> – Category C; crosses fetal blood‑brain barrier, use with caution.  </li>
</ul>
</div></details>
<details><summary><strong>5.4 Ancillary Medications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Simethicone</strong> – Category C; likely safe, no evaluated teratogenicity.  </li>
<li style="margin-left: 0px;"><strong>Glucagon</strong> – Category B; used for therapeutic purposes (e.g., to relax sphincter).  </li>
<li style="margin-left: 0px;"><strong>Topical lidocaine</strong> – Category B; may reduce gag reflex; advise patient to gargle and spit.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Radiation Exposure: Risks, Monitoring, and Long‑Term Effects  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Fetal Dose Thresholds &amp; Guidelines  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Organogenesis (weeks 2‑8): fetal sensitivity highest; deterministic effects reported &gt;100–200 mGy.  </li>
<li style="margin-left: 0px;">Deterministic threshold &lt;50 mGy not associated with observable effects.  </li>
<li style="margin-left: 0px;">International Commission on Radiological Protection: monitor if expected dose &gt;10 mGy.  </li>
</ul>
</div></details>
<details><summary><strong>6.2 Reported ERCP Radiation Doses  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Typical ERCP exposure range <strong>0.01–5.77 mGy</strong> (well below 10 mGy).  </li>
<li style="margin-left: 0px;">Study of 15 pregnant patients: mean fluoroscopy time <strong>14 s</strong>, estimated fetal dose <strong>0.4 mGy</strong> (range 0.001‑1.80 mGy).  </li>
</ul>
</div></details>
<details><summary><strong>6.3 Stochastic Effects &amp; Long‑Term Follow‑Up  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Childhood leukemia risk noted with fetal exposures as low as <strong>10 mGy</strong>; causality remains uncertain.  </li>
<li style="margin-left: 0px;">Limited case series: no definitive long‑term adverse events reported after diagnostic pelvic radiation ≤10 mGy.  </li>
<li style="margin-left: 0px;">Need for systematic, longitudinal registries to assess developmental outcomes.  </li>
</ul>
</div></details>
<details><summary><strong>6.4 Strategies to Minimize Radiation (Technical &amp; Procedural)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.4.1 Fluoroscopy‑Based Techniques  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Position patient <strong>far from x‑ray tube</strong>, image receptor <strong>close</strong> → dose reduction.  </li>
<li style="margin-left: 0px;">Use <strong>collimation</strong> to limit beam size; employ <strong>brief‑pulse, low‑dose settings</strong>.  </li>
<li style="margin-left: 0px;">Avoid digital acquisition modes that increase exposure.  </li>
</ul>
</div></details>
<details><summary><strong>6.4.2 Procedure‑Based Techniques  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Wire‑guided cannulation</strong> with bile aspirate as confirmation → may eliminate fluoroscopy.  </li>
<li style="margin-left: 0px;"><strong>Cholangioscopy‑assisted cannulation</strong> for direct visualization of ductal anatomy.  </li>
<li style="margin-left: 0px;"><strong>Real‑time transabdominal ultrasound guidance</strong> (Li et al.) to verify CBD access and stone clearance without radiation.  </li>
</ul>
</div></details>
<details><summary><strong>6.4.3 Positioning Adjustments  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Place <strong>grounding pad on right thorax</strong>, away from amniotic sac, to prevent current conduction through fetus during sphincterotomy.  </li>
</ul>
</div></details>
</div></details>
</div></details>
<details><summary><strong>7. Future Directions &amp; Research Priorities  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Data Aggregation &amp; Evidence Synthesis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Multi‑center registries needed to define best practices for maternal comorbidities (e.g., obesity) influencing endoscopic safety.  </li>
</ul>
</div></details>
<details><summary><strong>7.2 Radiation Technology Advancements  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Development of <strong>ultra‑low‑dose fluoroscopy</strong> and <strong>dose‑modulation algorithms</strong>; require prospective validation in pregnant cohorts.  </li>
</ul>
</div></details>
<details><summary><strong>7.3 Non‑Invasive &amp; Sedation‑Free Approaches  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transnasal endoscopes</strong> with larger channels → potential for diagnostic/therapeutic work without sedation.  </li>
<li style="margin-left: 0px;">Combination of <strong>ERCP + transabdominal US or cholangioscopy</strong> to reduce fluoroscopy time.  </li>
</ul>
</div></details>
<details><summary><strong>7.4 Longitudinal Outcomes Research  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Systematic follow‑up of children exposed in utero to endoscopic procedures; focus on neurodevelopment, growth, and oncologic risk.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Conclusions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopy is a <strong>critical tool</strong> for managing GI pathology during pregnancy when benefits outweigh risks.  </li>
<li style="margin-left: 0px;"><strong>Multidisciplinary coordination</strong> (gastroenterology, obstetrics, anesthesia) essential for optimal maternal‑fetal outcomes.  </li>
<li style="margin-left: 0px;">Key safety pillars: <strong>clear indication</strong>, <strong>second‑trimester timing</strong>, <strong>left lateral positioning</strong>, <strong>appropriate sedation</strong>, and <strong>radiation minimization</strong>.  </li>
<li style="margin-left: 0px;"><strong>ERCP</strong> remains safe but carries a modestly increased risk of post‑procedure pancreatitis; meticulous technique and dose reduction are paramount.  </li>
</ul>
</div></details>
<details><summary><strong>9. Practical Workflow Checklist for Endoscopy in Pregnancy  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Pre‑Procedure Planning  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Obstetric consultation</strong> obtained; document fetal gestational age and any maternal complications.  </li>
<li style="margin-left: 0px;">Verify <strong>indication clarity</strong>; if uncertain, perform non‑invasive imaging (RUQ US, MRCP) first.  </li>
<li style="margin-left: 0px;">Review <strong>medication list</strong> for FDA pregnancy categories; select Category B/C agents when possible.  </li>
<li style="margin-left: 0px;">Obtain <strong>informed consent</strong>: discuss aspiration risk, fetal hypotension/hypoxia, teratogenic potential, radiation exposure, and post‑procedure pancreatitis (ERCP).  </li>
</ul>
</div></details>
<details><summary><strong>9.2 Intra‑Procedure Management  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.2.1 Positioning &amp; Monitoring  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Place patient in <strong>left lateral tilt</strong> or left pelvic tilt; use pillow/wedge under right hip.  </li>
<li style="margin-left: 0px;">For gestations &gt;24 wks: attach <strong>electronic fetal heart rate monitor</strong> (if available).  </li>
<li style="margin-left: 0px;">Continuous maternal <strong>blood pressure, oxygen saturation</strong>, and <strong>airway protection</strong> monitoring.  </li>
</ul>
</div></details>
<details><summary><strong>9.2.2 Sedation Protocol  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Drug</th>
<th>Category</th>
<th>Typical Dose (Pregnant)</th>
<th>Notes</th>
</tr></thead>
<tbody>
<tr>
<td>Meperidine</td>
<td>B</td>
<td>25‑50 mg IV</td>
<td>Preferred narcotic; avoid high doses.</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>C</td>
<td>≤1 µg/kg IV</td>
<td>Short‑acting; safe low dose.</td>
</tr>
<tr>
<td>Propofol</td>
<td>B</td>
<td>0.5‑1 mg/kg bolus + infusion</td>
<td>Requires anesthesia support; monitor depth.</td>
</tr>
<tr>
<td>Midazolam</td>
<td>D (use if needed)</td>
<td>≤2 mg IV</td>
<td>Avoid first trimester; use minimal effective dose.</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Avoid benzodiazepines</strong> in first trimester unless absolutely necessary.  </li>
<li style="margin-left: 0px;">Maintain <strong>SpO₂ &gt; 95 %</strong>, avoid maternal hypoxia.  </li>
</ul>
</div></details>
<details><summary><strong>9.2.3 Radiation Safety (ERCP)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Set fluoroscopy to <strong>low‑dose, pulsed mode</strong>; limit exposure time &lt;30 s when possible.  </li>
<li style="margin-left: 0px;">Use <strong>collimation</strong> to confine beam to target area only.  </li>
<li style="margin-left: 0px;">Position <strong>image receptor close</strong>, x‑ray tube far from abdomen.  </li>
<li style="margin-left: 0px;">Employ <strong>wire‑guided cannulation</strong> or <strong>US‑guided confirmation</strong> to reduce fluoroscopy need.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9.3 Post‑Procedure Care  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Re‑assess <strong>fetal heart rate</strong> (Doppler) immediately after sedation wears off.  </li>
<li style="margin-left: 0px;">Monitor maternal vitals for at least <strong>30 min</strong>; watch for hypotension, bleeding, or pancreatitis signs.  </li>
<li style="margin-left: 0px;">Provide <strong>post‑procedure counseling</strong>: activity restrictions, signs of preterm labor, and when to seek care.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Summary Tables  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>10.1 Indications Overview (Table 1 Reconstructed)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Modality</th>
<th>Primary Indication(s)</th>
<th>Typical Trimester Preference</th>
</tr></thead>
<tbody>
<tr>
<td>Upper Endoscopy (EGD)</td>
<td>Persistent GI bleed, Mallory‑Weiss tear, suspected ulcer disease, refractory nausea/vomiting with pain</td>
<td>2nd trimester optimal; 1st if emergent</td>
</tr>
<tr>
<td>Flexible Sigmoidoscopy</td>
<td>IBD assessment, limited colonic evaluation, no full prep needed</td>
<td>Any trimester; 2nd preferred</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Suspected colon neoplasm, refractory diarrhea, unexplained GI bleed</td>
<td>2nd trimester best; 3rd with left tilt</td>
</tr>
<tr>
<td>ERCP</td>
<td>Symptomatic choledocholithiasis, biliary pancreatitis, cholangitis, duct injury</td>
<td>2nd trimester ideal; 1st acceptable supine</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>10.2 Medication Safety Summary (Table 2 Reconstructed)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Medication</th>
<th>FDA Category</th>
<th>Key Comment</th>
</tr></thead>
<tbody>
<tr>
<td>Meperidine</td>
<td>B</td>
<td>Preferred narcotic; non‑teratogenic</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>C</td>
<td>Short‑acting, safe low dose</td>
</tr>
<tr>
<td>Propofol</td>
<td>B</td>
<td>Requires anesthesia; limited 1st‑trimester data</td>
</tr>
<tr>
<td>Morphine</td>
<td>C</td>
<td>Crosses BBB; use cautiously</td>
</tr>
<tr>
<td>Midazolam</td>
<td>D</td>
<td>Use only if essential; avoid early pregnancy</td>
</tr>
<tr>
<td>Diazepam</td>
<td>D</td>
<td>Contraindicated</td>
</tr>
<tr>
<td>Naloxone</td>
<td>B</td>
<td>Rescue for opioid overdose</td>
</tr>
<tr>
<td>Simethicone</td>
<td>C</td>
<td>Likely safe, no teratogenicity data</td>
</tr>
<tr>
<td>Glucagon</td>
<td>B</td>
<td>Safe for therapeutic use</td>
</tr>
<tr>
<td>Topical lidocaine</td>
<td>B</td>
<td>Helpful for gag reflex</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>10.3 Radiation Dose Reduction Techniques (Table 3 Reconstructed)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Fluoroscopy‑Based</strong>: far from tube / close to receptor, collimation, brief‑pulse low‑dose mode, avoid digital acquisition.  </li>
<li style="margin-left: 0px;"><strong>Procedure‑Based</strong>: wire access with bile aspirate, cholangioscopy‑assisted cannulation, real‑time transabdominal US guidance.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Key Take‑Home Points  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Indication clarity</strong> supersedes procedural hesitancy; only proceed when maternal/fetal risk of non‑intervention exceeds procedural risks.  </li>
<li style="margin-left: 0px;"><strong>Second trimester</strong> is the safest window for most endoscopic interventions due to completed organogenesis and reduced uterine compression.  </li>
<li style="margin-left: 0px;"><strong>Left lateral positioning</strong> throughout the procedure mitigates aortic/IVC compression, preserving placental perfusion.  </li>
<li style="margin-left: 0px;"><strong>Sedation</strong> should favor Category B agents; limit benzodiazepines, especially in first trimester.  </li>
<li style="margin-left: 0px;"><strong>Radiation exposure</strong> during ERCP is typically far below harmful thresholds; employ dose‑reduction strategies rigorously.  </li>
<li style="margin-left: 0px;"><strong>Post‑procedure monitoring</strong> must include both maternal vitals and fetal heart rate assessment to detect early complications.  </li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
